Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Babington, P. W. Articles by Spiegel, D. R. Search for Related Content PubMed Citation Articles by Babington, P. W. Articles by Spiegel, D. R. Schizophrenia Spectrum Disorders Atypical Neuroleptics

Treatment of Catatonia With Olanzapine and Amantadine

Received August 14, 2006; revised October 29, 2006; accepted November 1, 2006. From Eastern Virginia Medical School Dept. of Psychiatry and Behavioral Sciences, Norfolk, VA. Send correspondence and reprint requests to David R. Spiegel, M.D., Eastern Virginia Medical School Dept. of Psychiatry and Behavioral Sciences, 825 Fairfax Ave., Norfolk, VA 23507. e-mail: spiegedr{at}evms.edu
© 2007 The Academy of Psychosomatic Medicine

Catatonia is a disorder characterized by mutism, posturing, echophenomena, and negativism. The preferred treatment for non-malignant catatonia is benzodiazepines, which often produce a reduction in symptoms within 24 hours. Presented here is a case report of a 19-year-old woman appearing in a catatonic state that did not respond to lorazepam. On the basis of emerging evidence that atypical antipsychotics and weak N-Methyl-D-Aspartate (NMDA) receptor-antagonists may effectively treat catatonia, we treated our patient with olanzapine and amantadine, which resulted in a dramatic reduction in her catatonic symptoms.

Get information about faster international access.

Privacy Policy

Copyright © 2007 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us